17:15 , Mar 28, 2017 |  BC Extra  |  Financial News

Antiva raises $22M series C round

Antiva Biosciences Inc. (Menlo Park, Calif.) raised $22 million in a series C round led by new investor Brace Pharma Capital. Also participating were new investors NS Investment, Osage University Partners and Alexandria Venture Investments...
02:03 , Aug 7, 2015 |  BC Extra  |  Financial News

Antiva raises $16M in series B

Antiva Biosciences Inc. (Menlo Park, Calif.) raised $16 million in a series B round co-led by new investors Canaan Partners and Sofinnova Ventures. Undisclosed existing investors also participated. The proceeds will be used to advance...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Hera Therapeutics preclinical data

In cultured human cell models, HTI-1968 blocked the replication of HPV types 11, 16, and 18 cells. Data were presented at the International Papillomavirus Conference in Seattle. HTI-1968 is a topical direct-acting antiviral. Hera Therapeutics...